GoodRx Holdings, Inc. (NASDAQ: GDRX) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 69.96 | EPS (ttm) | 0.05 | Insider Own | 43.01% | Shs Outstand | 346.63M | Perf Week | 19.87% |
| Market Cap | 1.28B | Forward P/E | 10.26 | EPS next Y | 0.36 | Insider Trans | 0.00% | Shs Float | 285.46M | Perf Month | 25.17% |
| Enterprise Value | 1.52B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 2.26% | Perf Quarter | 29.58% |
| Income | 16.58M | P/S | 1.62 | EPS this Y | 416.45% | Inst Trans | - | Short Ratio | 4.36 | Perf Half Y | 60.70% |
| Sales | 785.25M | P/B | 1.93 | EPS next Y | 15.72% | ROA | 0.69% | Short Interest | 6.46M | Perf YTD | 35.79% |
| Book/sh | - | P/C | 5.85 | EPS next 5Y | - | ROE | 2.61% | 52W High | 6.04 -36.66% | Perf Year | -15.21% |
| Cash/sh | - | P/FCF | 8.15 | EPS past 3/5Y | - | ROIC | 2.64% | 52W Low | 1.84 107.91% | Perf 3Y | -56.50% |
| Dividend Est. | - | EV/EBITDA | 10.22 | Sales past 3/5Y | 1.29% 7.66% | Gross Margin | 88.05% | Volatility | 8.06% 5.25% | Perf 5Y | -88.53% |
| Dividend TTM | - | EV/Sales | 1.93 | EPS Y/Y TTM | 43.54% | Oper. Margin | 10.25% | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.38 | Sales Y/Y TTM | -0.51% | Profit Margin | 2.07% | RSI (14) | 71.07 | Recom | 2.63 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.38 | EPS Q/Q | -22.22% | SMA20 | 16.66% | Beta | 1.60 | Target Price | 4.50 |
| Payout | 0.00% | Debt/Eq | 0.83 | Sales Q/Q | -4.43% | SMA50 | 24.78% | Rel Volume | 1.34 | Prev Close | 3.68 |
| Employees | 697 | LT Debt/Eq | 0.87 | Earnings | Nov 03 | SMA200 | 37.68% | Avg Volume | 1.42M | Price | 3.83 |
| IPO Date | Sep 23, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -2.66% 4.64% | Net Debt/EBITDA | 1.63 | Volume | 1,906,666 | Change | 3.94% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Goldman Sachs | Neutral | $3.50 → $4.00 |
| Aug-06-26 | Reiterated | Leerink Partners | $3.50 → $5.00 | |
| May-08-26 | Reiterated | Goldman Sachs | Neutral | $2.50 → $3.50 |
| Feb-27-26 | Downgrade | JP Morgan | Overweight → Neutral | |
| Feb-26-26 | Reiterated | Leerink Partners | $3.00 | |
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold | $2.75 |
| Dec-18-25 | Reiterated | Morgan Stanley | Equal Weight | $9.50 → $4.00 |
| Dec-08-25 | Initiated | Barclays | Underweight | $9.00 → $3.00 |
| Aug-11-25 | Reiterated | Deutsche Bank | Hold | $8.00 → $6.00 |
| Jun-10-24 | Reiterated | Morgan Stanley | Equal Weight | $9.50 |
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 785 | 797 | 792 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 93 | 58 | 48 | — | — | — | — | — | — | |
| Gross Profit | 691 | 739 | 744 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 434 | 446 | 485 | — | — | — | — | — | — | |
| Research and Development | 117 | 121 | 124 | — | — | — | — | — | — | |
| Other Operating Expense | 61 | 85 | 69 | — | — | — | — | — | — | |
| Operating Income | 82 | 87 | 66 | — | — | — | — | — | — | |
| Interest Expense | 41 | 43 | 53 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | 12 | 19 | — | — | — | — | — | — | |
| Net Income Before Taxes | 41 | 57 | 31 | — | — | — | — | — | — | |
| Income Taxes | 25 | 26 | 15 | — | — | — | — | — | — | |
| Consolidated Net Income | 16 | 30 | 16 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 16 | 30 | 16 | — | — | — | — | — | — | |
| Net Income | 16 | 30 | 16 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.05 | 0.09 | 0.04 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.05 | 0.09 | 0.04 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.04 | 0.09 | 0.04 | — | — | — | — | — | — | |
| EBITDA | 148 | 184 | 154 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 95.63 | 31.77 | 111.24 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.65 | 1.21 | 2.27 | — | — | — | — | — | — | |
| Gross Margin | 88.03 | 92.72 | 93.94 | — | — | — | — | — | — | |
| Operating Margin | 10.45 | 10.92 | 8.33 | — | — | — | — | — | — | |
| Net Margin | 2.04 | 3.76 | 2.02 | — | — | — | — | — | — | |
| Shares Outstanding | 339 | 356 | 386 | — | — | — | — | — | — | |
| Market Capitalization | 1,297 | 965 | 1,795 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McGinnis Christopher A | See Remarks | Jul 15 '26 | Option Exercise | 0.00 | 36,988 | 0 | 214,604 | Jul 16 |
| Barnes Wendy Lynn | See Remarks | Jul 15 '26 | Option Exercise | 0.00 | 277,288 | 0 | 789,860 | Jul 16 |
| Chan Thomas (TC) | Chief Accounting Officer | Jul 15 '26 | Option Exercise | 0.00 | 5,792 | 0 | 11,527 | Jul 16 |
| Chan Thomas (TC) | Chief Accounting Officer | Jun 15 '26 | Option Exercise | 0.00 | 4,069 | 0 | 6,804 | Jun 15 |
| Chan Thomas (TC) | Chief Accounting Officer | May 15 '26 | Option Exercise | 0.00 | 5,575 | 0 | 4,595 | May 15 |
| McGinnis Christopher A | See Remarks | May 15 '26 | Option Exercise | 0.00 | 44,779 | 0 | 197,342 | May 15 |
| McGinnis Christopher A | See Remarks | Apr 15 '26 | Option Exercise | 0.00 | 36,987 | 0 | 406,865 | Apr 15 |
| Barnes Wendy Lynn | See Remarks | Apr 15 '26 | Option Exercise | 0.00 | 277,288 | 0 | 633,028 | Apr 15 |
| REY-GIRAUD AGNES | Director | Mar 12 '26 | Option Exercise | 0.47 | 192,185 | 90,327 | 277,633 | Mar 13 |
| Nabiey Romin | Chief Accounting Officer | Mar 08 '26 | Option Exercise | 0.00 | 12,434 | 0 | 185,949 | Mar 09 |
| Nabiey Romin | Chief Accounting Officer | Feb 15 '26 | Option Exercise | 0.00 | 4,804 | 0 | 177,727 | Feb 17 |
| McGinnis Christopher A | See Remarks | Feb 15 '26 | Option Exercise | 0.00 | 179,120 | 0 | 179,120 | Feb 17 |
| Nabiey Romin | Chief Accounting Officer | Feb 08 '26 | Option Exercise | 0.00 | 12,663 | 0 | 178,138 | Feb 09 |
| Wagner Scott | Director | Jan 21 '26 | Option Exercise | 0.00 | 31,394 | 0 | 216,663 | Jan 21 |
| Barnes Wendy Lynn | See Remarks | Jan 15 '26 | Option Exercise | 0.00 | 665,302 | 0 | 516,919 | Jan 15 |